Acadia Pharmaceuticals (NASDAQ: ACAD) aspires to become a big player in the neuroscience market. Eli Lilly (NYSE: LLY) already is one. But aside from their common interest in this therapeutic category, there's little in common between these two drugmakers.Investors considering buying shares of Acadia or Lilly have a stark contrast -- beaten-down biotech, or relatively boring big pharma.